Haoxi Health Technology (HAO) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
29 Nov, 2025Company overview and business model
Operates as an online marketing solution provider in China, primarily serving healthcare industry advertisers.
Offers one-stop online marketing services, focusing on short video ads, content production, and campaign optimization.
Utilizes proprietary data analysis software, “Bidding Compass,” to enhance ad placement efficiency and ROI.
Maintains direct and agent-based relationships with major media platforms, especially ByteDance’s Ocean Engine.
Has served approximately 2,000 advertisers since 2018, with a growing client base and strong industry focus.
Financial performance and metrics
Revenue for the six months ended December 31, 2023 was $23.50 million, up 157% from $9.16 million in the prior year period.
Net income for the same period was $760,198, a 70% increase from $447,046.
Fiscal year 2023 revenue was $28.23 million, up 75% from $16.16 million in 2022; net income was $969,752, up from $244,587.
Gross margin improved to 7.3% in FY2023 from 4.0% in FY2022, mainly due to direct contracts with Ocean Engine.
Cash and cash equivalents as of December 31, 2023 were $1.11 million; company expects negative operating cash flows as it scales.
Use of proceeds and capital allocation
Plans to use approximately 60% of net proceeds for working capital and general corporate purposes, including sales and marketing.
About 30% allocated for acquiring or investing in technologies, solutions, or businesses to enhance data analysis and customer return rates.
Remaining 10% intended for hiring experienced employees to strengthen internal controls and compliance.
Latest events from Haoxi Health Technology
- All AGM proposals, including share consolidation and director re-elections, passed with over 99% approval.HAO
AGM 202510 Jan 2026 - Registering up to $80M in securities, with strong revenue growth and high PRC regulatory risk.HAO
Registration Filing16 Dec 2025 - Raising up to $80M on Nasdaq, the company targets healthcare marketing in China amid regulatory risks.HAO
Registration Filing16 Dec 2025 - FY2025 revenue fell 32% while net income surged to $3.88M, with ongoing regulatory and supplier risks.HAO
Q4 202412 Dec 2025 - Raising $9.09M to expand healthcare-focused digital marketing in China, but faces regulatory and concentration risks.HAO
Registration Filing29 Nov 2025 - Chinese healthcare-focused ad tech firm seeks $11.4M via Nasdaq unit offering, CEO retains control.HAO
Registration Filing29 Nov 2025 - Offering 2,093,802 units at $5.97 each, the company targets healthcare ads but faces regulatory and concentration risks.HAO
Registration Filing29 Nov 2025 - Rapid revenue growth, high regulatory risk, and CEO control define this complex offering.HAO
Registration Filing29 Nov 2025 - Rapid revenue growth, but high supplier concentration and regulatory risks; $11.4M IPO with warrants.HAO
Registration Filing29 Nov 2025